Efficacy and Safety of EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma: a Single-center, Single-arm Phase II Trial

Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells. By combining EBV lytic induction strategy with standard chemo-immunotherapy, this study aims to create a synergistic anti-tumor effect and improve clinical outcomes for patients with recurrent/metastatic NPC (r/m NPC). This is a phase II, single-center, single-arm clinical trial designed to evaluate the efficacy and safety of a novel combination therapy in patients with r/m EBV-positive NPC.

Start Date19 Aug 2025

Sponsor / Collaborator

Sun Yat-Sen University

NCT06798909

/ RecruitingPhase 3IIT

Kidney Transplant Preemptive Therapy or Prophylaxis (KPoP) for CMV Prevention in D+R- Recipients

This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily [both dose adjusted per Food and Drug Administration (FDA) label] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study.
Estimated Time to Complete Enrollment: 4 years

Start Date22 Jul 2025

Sponsor / Collaborator

The University of California, San Francisco

[+1]

CTRI/2025/06/088638

/ Not yet recruitingNot Applicable

Open-label, prospective, multi-center, single-arm, academic clinical trial of oral Valganciclovir (VGCV) as pre-emptive therapy for low-risk cytomegalovirus reactivation following alloHCT in children - VALOR

Start Date01 Jul 2025

Sponsor / Collaborator-

100 Clinical Results associated with Valganciclovir Hydrochloride

100 Translational Medicine associated with Valganciclovir Hydrochloride

100 Patents (Medical) associated with Valganciclovir Hydrochloride

1,927

Literatures (Medical) associated with Valganciclovir Hydrochloride

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Cost-utility and budget impact analyses of valganciclovir for cytomegalovirus retinitis in patients with human immunodeficiency virus in Thailand

Article

Author: Hemapanpairoa, Jatapat ; Kulthanachairojana, Nattanichcha ; Wongwian, Tippawan

Background:

Cytomegalovirus retinitis (CMVR) is an opportunistic infection frequently seen in people living with HIV (PLHIV) and can cause blindness. Intravenous (IV) ganciclovir is a typical CMVR treatment in Thailand, but oral valganciclovir is a more convenient alternative. However, its cost-effectiveness and budget impact remain unclear. Therefore, this study aimed to analyse the cost-utility and budget impact of oral valganciclovir compared with IV ganciclovir for CMVR treatment in PLHIV in Thailand.

Methods:

A hybrid decision tree/Markov model was developed to estimate costs, quality-adjusted life years (QALYs), and life years (LYs). Cost, utility, and probability parameters were obtained from the published literature and national databases. A cost-utility analysis was performed to estimate the incremental cost-effectiveness ratios, whereas a budget impact analysis (BIA) was performed to assess the financial implications. Sensitivity analyses were performed to assess model uncertainty.

Results:

Oral valganciclovir was the dominant treatment, providing higher QALYs (3.50 vs. 3.23) and LYs (4.78 vs. 4.75) and lower total costs (133,630 THB vs. 163,024 THB) than IV ganciclovir. One-way sensitivity analysis revealed that retinal detachment probability, drug cost, and inpatient service cost were the most influential parameters. Probabilistic sensitivity analysis revealed that 94.3% of the simulations placed oral valganciclovir in the dominant quadrant. BIA revealed an annual cost reduction of 6,408,714 THB when replacing IV ganciclovir with oral valganciclovir.

Conclusion:

Oral valganciclovir was cost-effective and demonstrated budget reduction compared with IV ganciclovir. These findings provide valuable insights into enhancing CMVR management and ensuring efficient healthcare resource allocation.

01 Sep 2025·PEDIATRIC TRANSPLANTATION

Letermovir and Tacrolimus Drug–Drug Interaction in a Pediatric Kidney Transplant Patient: A Case Report and Review of the Literature

Review

Author: Berger, Iona ; Haubrich, Kathryn ; Matsuda‐Abedini, Mina

ABSTRACT:

Background:

Cytomegalovirus (CMV) viremia is one of the most common opportunistic infections following solid organ transplant (SOT) in pediatric patients and can be associated with significant morbidity. Valganciclovir is the preferred antiviral medication used for CMV prophylaxis in high‐risk kidney transplant recipients, but its use is limited by myelosuppression. Letermovir is an alternative antiviral medication with lower rates of neutropenia. Letermovir has been implicated in many potential drug–drug interactions, including in combination with tacrolimus.

Methods:

This report describes the case of a 6‐year‐old girl, 2 months post‐kidney transplant, at risk for CMV, who received letermovir for CMV prophylaxis after developing neutropenia while receiving valganciclovir. Her maintenance immunosuppression included tacrolimus. This report describes the drug–drug interaction of letermovir and tacrolimus, the dose adjustments required, and summarizes the available literature on the interaction.

Results:

While on concurrent letermovir and tacrolimus, the patient required a 36% tacrolimus dose reduction and additional therapeutic drug level monitoring.

Conclusion:

This case adds to the current limited data on the interaction of letermovir and tacrolimus in the pediatric SOT population.

01 Sep 2025·INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY

The effect of (val)ganciclovir on hearing in children with congenital cytomegalovirus infection

Article

Author: Keymeulen, Annelies ; Desloovere, Christian ; Boudewyns, An ; Schatteman, Isabelle ; De Leenheer, Els ; Van Hoecke, Helen ; Kuhweide, Rudolf ; Muylle, Marie ; Gilles, Annick ; Royackers, Liesbeth ; Dhooge, Ingeborg ; Verstreken, Margriet ; Acke, Frederic ; De Cuyper, Elise

OBJECTIVES:

To assess the effect of (val)ganciclovir on long-term hearing outcome.

METHODS:

This matched cohort study presents multicentric data of the Flemish CMV registry (Belgium) collected over 16 years. Treated and untreated cCMV-infected children with a minimal four-year audiological follow-up were included. Primary outcome was hearing evolution. Exact matching for risk factors of spontaneous hearing evolution was performed between the treated and untreated group. The average marginal treatment effect was calculated using a pooled regression model.

RESULTS:

Of the 525 children, 98 (18.7 %) were treated. Antiviral therapy did not significantly result in more hearing improvement (RR,1.56; 95 % CI,0.48 to 4.93) or less hearing deterioration (RR,0.89; 95 % CI,0.61 to 1.25). Treatment of children with unilateral congenital hearing loss with valganciclovir for six weeks prevented contralateral late-onset hearing loss compared to untreated children (RR,2.49∗10^-8; 95 % CI,9.19∗10^-9 to 7.71∗10^-8). Similarly, late-onset hearing loss could be prevented in symptomatic children with bilateral normal hearing treated with ganciclovir for six weeks (RR,3.65∗10^-7; 95 % CI,2.16∗10^-7 to 6.21∗10^-7). Prolongation from six weeks to six months showed no beneficial effect on hearing improvement (RR,4.61∗10^-8; 95 % CI,1.07∗10^-8 to 2.32∗10^-7), hearing deterioration (RR,1.21; 95 % CI,0.43 to 2.25), or late-onset hearing loss (RR,1.95; 95 % CI,0.63 to 5.93).

CONCLUSIONS:

(Val)ganciclovir for six weeks prevented late-onset hearing loss. No additional benefit of a six-month therapy was found. These novel findings can aid in treatment decision making. Future studies with a larger sample size and investigation on the effect of valganciclovir on long-term neurological outcome are needed.

104

News (Medical) associated with Valganciclovir Hydrochloride

26 Jun 2025

·www.echemi.com

Merck’s New CMV Drug Approved in China Targets Nearly 40000 HSCT Patients

On June 23, 2025, Merck announced that its novel non-nucleoside cytomegalovirus (CMV) inhibitor, Letermovir, in both tablet and injectable forms, has been approved by the National Medical Products Administration (NMPA) for use in children aged 6 months and above, weighing ≥6kg. The newly approved indication covers the prevention of CMV infection and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients who are CMV-seropositive (R+), including adults and children. According to Merck, Letermovir is the first and only CMV prevention therapy in China available for both pediatric and adult HSCT patients. CMV, a prevalent herpes virus, poses a severe threat to transplant recipients, significantly increasing transplant-related mortality rates. In China, CMV infection is widespread, with 60%-80% of infants testing positive for antibodies. Children, who lack fully developed immune systems, face an increased risk of CMV reactivation after transplantation. Data shows that in 2022 and 2023, there were 39,918 HSCT recipients in China, of which 9,860 were children—accounting for 1 in every 4 transplant patients. The approval of Letermovir addresses a critical unmet need in CMV prevention for this vulnerable group. Previously approved CMV inhibitors in China include Roche’s ganciclovir and valganciclovir, while domestic companies such as Zhejiang Asia-Pacific Pharmaceutical and Shanghai Pharma have also entered the market with generic versions. However, Letermovir offers a novel mechanism of action, making it a game-changing option for CMV prevention in HSCT patients, particularly children.

Drug ApprovalImmunotherapyCell Therapy

14 May 2025

·www.prnewswire.com

Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market | DelveInsight

The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes its use as a first-line treatment in combination with platinum-based chemotherapy, as well as a monotherapy option for later-stage metastatic disease. This marks the first FDA approval for a biologic developed in-house by Akeso, signifying the Hong Kong-based company's debut in the US nasopharyngeal carcinoma market. LAS VEGAS, May 14, 2025 /PRNewswire/ -- Nasopharyngeal carcinoma is a rare type of cancer that originates in the nasopharynx, the upper part of the throat behind the nose. It is strongly associated with Epstein-Barr virus (EBV) infection. Unlike many other head and neck cancers, NPC has distinct genetic, viral, and environmental risk factors. As per DelveInsight's analysis, in 2023, there were around 67K incident cases of head and neck cancer and around 2,300 cases of nasopharyngeal cancer in the United States. Due to their location and extent of spread, nasopharyngeal cancers are often not suitable for surgical removal. These cancers are usually managed with a combination of chemotherapy and radiation therapy, often followed by additional chemotherapy. If the cancer recurs, it may be treated with another round of radiation, frequently using brachytherapy. In carefully selected cases, skull base resection may be considered as an alternative to radiation. LOQTORZI (toripalimab-tpzi) is an advanced anti-PD-1 monoclonal antibody that inhibits PD-L1 from binding to the PD-1 receptor at a distinct, high-affinity site, thereby enhancing antitumor immune responses and improving overall survival across multiple cancer types. In October 2023, the FDA approved LOQTORZI in combination with cisplatin and gemcitabine as a first-line treatment for adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. Additionally, the FDA approved toripalimab-tpzi as a monotherapy for adults with recurrent, unresectable, or metastatic nasopharyngeal carcinoma that has progressed following platinum-based chemotherapy. The combination therapy's efficacy was demonstrated in the JUPITER-02 clinical trial. Learn more about the nasopharyngeal carcinoma treatment options @ Nasopharyngeal Carcinoma Treatment Market In April 2025, the FDA approved penpulimab-kcqx, a distinct PD-1 monoclonal antibody, for use alongside cisplatin or carboplatin and gemcitabine as a first-line treatment for adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. Additionally, the FDA authorized penpulimab-kcqx as a standalone treatment for adults with metastatic non-keratinizing NPC who have experienced disease progression following platinum-based chemotherapy and at least one other prior therapy. Penpulimab-kcqx was independently developed by Akeso, with further development and commercialization carried out through its joint venture with Chia Tai-Tianqing Pharmaceutical Group. This approval marks the first time an innovative biologic developed internally by Akeso has received FDA clearance, signifying a major milestone. It reflects the strength of the clinical data supporting penpulimab-kcqx and signifies Akeso's successful entry into the US regulatory landscape. The achievement showcases Akeso's innovation in drug development and its dedication to meeting high global standards in pharmaceutical quality. The FDA's decision affirms Akeso's international development and expansion strategy and provides a solid platform for the company to advance its clinical programs in the global therapeutics arena. In China, penpulimab-kcqx is already approved for two uses: as a first-line treatment and as a second-line or later therapy for advanced NPC. The recent US approval introduces a new immunotherapy option for American patients with advanced NPC. This regulatory approval was based on findings from the global Phase III AK105-304 trial and the pivotal AK105-202 study, both of which supported the Biologics License Applications (BLA) for penpulimab-kcqx. These trials confirmed the drug's clinical efficacy and favorable safety profile across different stages of metastatic NPC treatment. AK105-304, a randomized, double-blind international Phase III trial, enrolled patients from various ethnic backgrounds. The results will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting. Previously, penpulimab-kcqx had received Breakthrough Therapy Designation (BTD), Orphan Drug Designation (ODD), and Fast Track Designation (FTD) from the FDA, emphasizing the urgent need for effective NPC treatments. To know more about the new treatment for nasopharyngeal carcinoma, visit @ FDA-approved Drugs for Nasopharyngeal Carcinoma Triggered by promising advances in immunotherapy, there has been growing interest in the use of immune checkpoint inhibitors (ICI), specifically anti-programmed death-1 or programmed death-1 ligand (PD-1/PD-L1) therapies in the treatment of nasopharyngeal carcinoma. Some of the drugs in the pipeline include Nana-val (Viracta Therapeutics), Tislelizumab (BeiGene), PRO1160 (Genmab/ProfoundBio), and others. Discover which therapies are expected to grab major nasopharyngeal carcinoma drug market share @ New Medicine for Nasopharyngeal Carcinoma TEVIMBRA is a humanized IgG4 monoclonal antibody targeting PD-1, engineered to reduce its interaction with Fc-gamma (Fcγ) receptors on macrophages. This design supports the immune system's ability to recognize and combat tumors. Preclinical research has shown that when PD-1 antibodies bind to Fcγ receptors on macrophages, it can reduce their anti-tumor efficacy by triggering macrophage-driven destruction of T-effector cells. Nanatinostat, developed by Viracta, is an orally administered histone deacetylase (HDAC) inhibitor with selectivity for certain Class I HDAC isoforms. These isoforms are crucial for reactivating viral genes that are epigenetically suppressed in cancers associated with Epstein-Barr virus (EBV). Nanatinostat is being evaluated as part of an all-oral regimen called Nana-val, in combination with the antiviral valganciclovir, for the treatment of various EBV-related cancers. Discover more about drugs for nasopharyngeal carcinoma in development @ Nasopharyngeal Carcinoma Clinical Trials Market The anticipated launch of these emerging nasopharyngeal carcinoma treatments are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the nasopharyngeal carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for nasopharyngeal carcinoma in the 7MM is expected to grow at a significant CAGR by 2034. This expansion across the 7MM will be due to the rising awareness of the disease and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. DelveInsight's latest published market report titled N asopharyngeal Carcinoma Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the nasopharyngeal carcinoma country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The nasopharyngeal carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Incident Cases of Nasopharyngeal Carcinoma Gender-specific Incident Cases of Nasopharyngeal Carcinoma Age-specific Incident Cases of Nasopharyngeal Carcinoma Stage-specific Incident Cases of Nasopharyngeal Carcinoma Treated Cases of Nasopharyngeal Carcinoma The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM nasopharyngeal carcinoma market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this nasopharyngeal carcinoma market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the nasopharyngeal carcinoma market. Also, stay abreast of the mitigating factors to improve your market position in the nasopharyngeal carcinoma therapeutic space. Related Reports Head and Neck Cancer Market Head and Neck Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HNC companies, including CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, among others. Head and Neck Cancer Pipeline Head and Neck Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HNC companies, including Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., among others. Head and Neck Squamous Cell Carcinoma Market Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HNSCC companies, including VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, Merus, PureTech Health, Rakuten Medical, Jacobio Pharmaceuticals , among others. Recurrent Head and Neck Squamous Cell Carcinoma Pipeline Recurrent Head and Neck Squamous Cell Carcinoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent HNSCC companies, including AstraZeneca, Astellas, GlaxoSmithKline, Boehringer Ingelheim, Merck, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyPhase 3Drug ApprovalFast TrackOrphan Drug

05 Mar 2025

·www.pharmaindustrial-india.com

Zydus Lifesciences Introduces ANVIMO for Kidney and HSCT Transplant Patients

Zydus has developed ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. ANVIMO will be available in dosages of 240 mg and 480 mg. CMV infection remains one of the most serious complications in transplant patients, often leading to graft failure, decreased survival and prolonged hospital stays. Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone marrow suppression. Letermovir provides a safer, well-tolerated, and effective alternative, offering superior safety and reduced side effects while improving transplant outcomes. Transplantation is a life-saving but financially burdensome procedure in India. The high cost of post-transplant care, particularly CMV prophylaxis, adds to the burden. Until now, innovator Letermovir 240 mg was imported at INR 5+ lakh per month, severely limiting access. With the launch of ANVIMO, Zydus has significantly reduced the cost by 91 percent of the innovator price, making treatment of CMV prophylaxis significantly more affordable for Indian patients. ANVIMO has established bioequivalence with the reference drug, ensuring quality at a fraction of the cost. Speaking on the launch, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, "The introduction of ANVIMO marks a new era in bone marrow transplant and kidney transplant care in India. By making this critical therapy affordable and accessible, we are reinforcing our commitment to delivering world-class healthcare solutions. Our mission is to ensure that transplant patients get access to affordable, life-saving treatment." With ANVIMO, Zydus Lifesciences is transforming CMV prophylaxis in India, ensuring that more transplant patients receive timely, effective, and affordable care, ultimately improving survival rates and quality of life.

Drug ApprovalCell Therapy

100 Deals associated with Valganciclovir Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D03256	Valganciclovir Hydrochloride	J05AB14	DB01610

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Virus Diseases	China	Roche Pharma (Schweiz) AG	13 Dec 2005
Acquired Immunodeficiency Syndrome	Japan	Mitsubishi Tanabe Pharma Corp.	05 Nov 2004
Cytomegalovirus Infections	Australia	Pharmaco (NZ) Ltd.	17 Jun 2002
Cytomegalovirus Retinitis	United States	CHEPLAPHARM Arzneimittel GmbH	29 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematopoietic stem cell transplantation	Phase 3	United States	Roche Pharma AG	01 Nov 2001
HIV Infections	Phase 3	Canada	Hoffmann-La Roche, Inc.	01 Jan 1997
Hearing Loss, Sensorineural	Phase 2	United States	Genentech, Inc.	31 Aug 2018
Chronic Lymphocytic Leukemia	Phase 2	United States	Roche Pharma AG	01 Sep 2003
Human herpesvirus 8 infection	Phase 2	United States	Hoffmann-La Roche, Inc.	01 Dec 2002
Idiopathic Pulmonary Fibrosis	Phase 1	United States	Genentech, Inc.	03 Jan 2018
Cystic Fibrosis	Phase 1	United States	Hoffmann-La Roche, Inc.	01 Dec 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01329185 (Pubmed) Manual	Phase 2	EBV viremia \| Cytomegalovirus viremia	137	Valganciclovir	tpxfdfmqzk(wyjxgkxsjq) = pglslkvkad nxxhmagzid (qfbwonjqly ) View more	Positive	01 Jun 2024
				Valganciclovir	tpxfdfmqzk(wyjxgkxsjq) = lnaevkvzbg nxxhmagzid (qfbwonjqly ) View more
NCT02927067 (AURORA, Pubmed)	Phase 3	Cytomegalovirus Infections	-	Valganciclovir (dose-adjusted for renal clearance)	ihdaqxckqd(dchwfjogep) = kcxcfohvxh hieemdppvk (ujkimsweln ) View more	Negative	30 Nov 2023
ERA2023	Not Applicable	Cytomegalovirus Infections	33	Low-dose oral valganciclovir (450 mg twice daily)	vpsapdarix(wczdrgeokz) = ilqotpvavr mqljjccwib (cwzkcgrcjt, 311.24–826.25)	-	15 Jun 2023
AACR2023 Manual	Phase 1	Recurrent Prostate Carcinoma	15	Ad5-yCD/mutTKSR39rep-hIL-12+5-fluorocytosine+Valganciclovir	hldibienbv(iramgdrcfp) = hnfwykeqoo ofhwxovulj (xxzmctqinl ) View more	Positive	14 Apr 2023
ACTRN12613000554763 (Pubmed \| J Am Soc Nephrol)	Not Applicable	Renal transplant rejection	140	Valganciclovir prophylaxis	jfybsvtlxh(avvszmlkvg) = zpbvomciho gguoqciwqq (buelfpmjyj ) View more	-	02 Feb 2023
				Preemptive therapy	jfybsvtlxh(avvszmlkvg) = zianvaoptw gguoqciwqq (buelfpmjyj ) View more
NCT03301415 (CTgov)	Phase 2	Cytomegalovirus Infections	7	Valganciclovir	jtlrunbnmr = hdwyjftegu lgbaqqbcci (kmvsdtxjfy, wqkftldbsx - wjzahlheeb) View more	-	26 Jan 2023
NCT02871401 (CTgov)	Phase 1	Idiopathic Pulmonary Fibrosis	31	Valganciclovir (Valganciclovir)	xbsmzzafok = otctkosnfr joqsrrqkjh (ybzplahpmk, iavssrjexh - kbttgoofyt) View more	-	29 Apr 2022
				Placebo (Placebo)	xbsmzzafok = eqitbhsohi joqsrrqkjh (ybzplahpmk, rprxmosiry - ckhvdaabog) View more
NCT01649869 (CTgov)	Phase 2	Hearing Loss \| Cytomegalovirus Infections \| Hearing Loss, Sensorineural	54	Placebo (Placebo)	mdmswzpzdv = fvnqtxoqoz rzbpjjapxz (ddoajqnpbm, nmulxptnko - ziujygffwf) View more	-	02 Jun 2021
				Valganciclovir (Active)	mdmswzpzdv = xkvwxdrpjy rzbpjjapxz (ddoajqnpbm, xvgklkrggt - lgicoamwga) View more
NCT02871401 (Pubmed)	Phase 1	Idiopathic Pulmonary Fibrosis Add-on	31	Valganciclovir 900 mg	eedydmbixq(aenetdaffw) = bftdefgtek fjuayoyhqr (psvqnmeiyr )	-	19 Mar 2021
				Placebo	eedydmbixq(aenetdaffw) = manuyzttfa fjuayoyhqr (psvqnmeiyr )
NCT00372229 (VIPP, CTgov)	Phase 3	Cytomegalovirus Infections	299	Ganciclovir+Valganciclovir (Pre-emptive CMV Therapy)	oxlpkupida = sgjgtuhpjw kfuldfjaet (wfjqtbhuvz, nobpgfcsvn - pqpgtakgqg) View more	-	11 Mar 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis